Clinical Trial Update: Irinotecan/Cetuximab Followed by XELOX/Cetuximab vs the Reverse Sequence in Metastatic CRC [Phase 2]

View source ↗

Summary

Phase 2 trial comparing sequencing of irinotecan/cetuximab and XELOX/cetuximab in metastatic colorectal cancer; the study status is terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• Camptosar (irinotecan)
• ERBITUX (cetuximab)
• Eloxatin (oxaliplatin)
• Xeloda (capecitabine)

Snippet

Sponsor: Hellenic Oncology Research Group | Conditions: Colorectal Cancer | Phase 2 | Status: TERMINATED